MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States. Its lead product candidate is AFREZZA inhalation powder, an insulin that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. The company is also developing MedTone and Dreamboat inhaler devices. MannKind Corporation was founded in 1991 and is headquartered in Valencia, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool

• [03/03/2015 17:45 PST] Market Maker Surveillance Report. MNKD, Bearishly Biased Price Friction For Tuesday, March 3rd 2015
• [02/17/2015 05:07 PST] MNKD, Expected to Trade Lower After Bearish Insider Trading
• [02/13/2015 08:57 PST] MNKD Expected to Trade Down After Bearish Patterns Develop
• [02/10/2015 05:09 PST] MNKD, Expected to Trade Lower After Bearish Insider Trading
• [02/05/2015 05:12 PST] MNKD, Expected to Trade Lower After Bearish Insider Trading
• [02/04/2015 05:08 PST] MNKD Expected to Trade Down After Bearish Patterns Develop
• [01/28/2015 04:40 PST] Mannkind Corp (NASDAQ:MNKD), Up By 5.03% ($0.32) From $6.360 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [01/28/2015 04:40 PST] MNKD Expected to Trade Up After Bullish Patterns Develop
• [01/02/2015 05:12 PST] MNKD Expected to Trade Down Short Term